Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Dynamic Changes of Key Gene Mutations in the Disease Course of Patients with Chronic Myelomonocytic Leukemia

Xin Yan, Sr., Chunhua Song, Zheng Ge

Blood (2024) 144 (Supplement 1): 6743.

https://doi.org/10.1182/blood-2024-206853

Published: 2024

Journal Articles

Dynamic Changes of Genetic Mutations in AML Patients from Diagnosis to Complete Remission and Relapse

Xin Yan, Sr., Chunhua Song, Zheng Ge

Blood (2024) 144 (Supplement 1): 6108.

https://doi.org/10.1182/blood-2024-207314

Published: 2024

Journal Articles

Newly-Acquired and Clonally-Increased Mutations in TP53 and RAS Pathways Promote Progressive Disease and Leukemic Transformation in Patients with Myelodysplatic Neoplasms

Xin Yan, Sr., Yulu Tian, Yan Gu, Chunhua Song, Zheng Ge

Blood (2024) 144 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2024-206378

Published: 2024

Journal Articles

Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy

Zhenkun Wang, Zhi-Wei Zhang, Zhong-Shi Lyu, Tong Xing, Mi Liang, Mengzhu Shen, Chen-Yuan Li, Xin-Yan Zhang, Dan-Dan Chen, Ya-Zhe Wang, Li-Juan Hu, Hao Jiang, Qian Jiang, Yuan Kong, Xiao-Jun Huang

Blood (2024) 144 (Supplement 1): 2684.

https://doi.org/10.1182/blood-2024-201354

Published: 2024

Journal Articles

Validation of the 5 th Edition of the World Health Organization Classification of Myelodysplastic Neoplasms on 852 Consecutive De Novo Patients from a Single Institute

Yudi Zhang, Junying Wu, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Lijuan Pan, Bing Li, Huijun Wang, Xin Yan, Jingye Gong, Robert Peter Gale, Zhijian Xiao

Blood (2022) 140 (Supplement 1): 1343–1345.

https://doi.org/10.1182/blood-2022-160131

Published: 2022

Journal Articles

Mutational Landscape, Clonal Evolution and Prognostic Effect of Non-Driver Mutations during Disease Progression of Primary Myelofibrosis

Xin Yan, Zefeng Xu, Shiqiang Qu, Tiejun Qin, Gang Huang, Zhijian Xiao, Bing Li

Blood (2022) 140 (Supplement 1): 3965–3967.

https://doi.org/10.1182/blood-2022-165185

Published: 2022

Journal Articles

Unique Clinical Features and Mutation Profile in De Novo Myelodysplastic Syndromes with MF-1 and a Proposed Model for Distinguishing MDS with MF-2/3 from TN-PMF Based on Clinical and Genetic Covariates

Junying Wu, Wenjun Zhang, Peihong Zhang, Tiejun Qin, Zefeng Xu, Qi Sun, Yujiao Jia, Shiqiang Qu, Bing Li, Huijun Wang, Lijuan Pan, Jinqin Liu, Yudi Zhang, Xin Yan, Robert Peter Gale, Zhijian Xiao

Blood (2022) 140 (Supplement 1): 4058–4059.

https://doi.org/10.1182/blood-2022-163019

Published: 2022

Journal Articles

Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism

Xin-Yan Pei, MD, Michael W Sanderson, BS, Leena E Youssefian, M.S, Jessica Felthousen, BS, Lora B Kramer, BS, Yun Dai, PhD, Steven Grant, MD

Blood (2014) 124 (21): 4763.

https://doi.org/10.1182/blood.V124.21.4763.4763

Published: 2014

Journal Articles

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis

Shuang Chen, Yu Zhang, Liang Zhou, Yun Leng, Hui Lin, Maciej Kmieciak, Xin-Yan Pei, Richard Jones, Robert Z. Orlowski, Yun Dai, Steven Grant

Blood (2014) 124 (17): 2687–2697.

https://doi.org/10.1182/blood-2014-03-564534

Published: 2014

Includes: Supplemental data

Journal Articles

Bim-Targeting Therapy Circumvents Adaptive Bortezomib-Resistance In Myeloma Through a Novel Cross-Link Between Autophagy and Apoptosis

Shuang Chen, MD/PhD, Yun Dai, MD, PhD, Yu Zhang, PhD, Liang Zhou, MD/PhD, Hui Lin, MD, Xin-Yan Pei, Robert Z. Orlowski, M.D., Ph.D., Steven Grant, MD

Blood (2013) 122 (21): 601.

https://doi.org/10.1182/blood.V122.21.601.601

Published: 2013

Journal Articles

Cytokinetically quiescent (G 0 /G 1 ) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2

Xin-Yan Pei, Yun Dai, Leena E. Youssefian, Shuang Chen, Wesley W. Bodie, Yukie Takabatake, Jessica Felthousen, Jorge A. Almenara, Lora B. Kramer, Paul Dent, Steven Grant

Blood (2011) 118 (19): 5189–5200.

https://doi.org/10.1182/blood-2011-02-339432

Published: 2011

Includes: Supplemental data

Journal Articles

Disruption of Src function potentiates Chk1-inhibitor–induced apoptosis in human multiple myeloma cells in vitro and in vivo

Yun Dai, Shuang Chen, Rena Shah, Xin-Yan Pei, Li Wang, Jorge A. Almenara, Lora B. Kramer, Paul Dent, Steven Grant

Blood (2011) 117 (6): 1947–1957.

https://doi.org/10.1182/blood-2010-06-291146

Published: 2011

Includes: Supplemental data

Journal Articles

Bortezomib Interacts Synergistically with Belinostat to Induce Apoptosis In Human Acute Myeloid and Lymphoid Leukemia Cells

Yun Dai, Shuang Chen, Li Wang, Xin-Yan Pei, Lora Kramer, Paul Dent, Steven Grant, MD

Blood (2010) 116 (21): 3266.

https://doi.org/10.1182/blood.V116.21.3266.3266

Published: 2010

Journal Articles

Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism.

Yun Dai, MD, PhD., Shuang Chen, MD, PhD, Xin-Yan Pei, MD, Viswanathan Ramakrishnan, Ph.D, Michael Wang, MD, MS., Robert Orlowski, PhD, Paul Dent, PhD, Steven Grant, MD

Blood (2009) 114 (22): 297.

https://doi.org/10.1182/blood.V114.22.297.297

Published: 2009

Journal Articles

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor–induced DNA damage in vitro and in vivo in human multiple myeloma cells

Yun Dai, Shuang Chen, Xin-Yan Pei, Jorge A. Almenara, Lora B. Kramer, Charis A. Venditti, Paul Dent, Steven Grant

Blood (2008) 112 (6): 2439–2449.

https://doi.org/10.1182/blood-2008-05-159392

Published: 2008

Includes: Supplemental data

Journal Articles

Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate

Yun Dai, Shuang Chen, Charis A. Venditti, Xin-Yan Pei, Tri K. Nguyen, Paul Dent, Steven Grant

Blood (2008) 112 (3): 793–804.

https://doi.org/10.1182/blood-2007-10-116376

Published: 2008

Includes: Supplemental data

Journal Articles

MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism

Xin-Yan Pei, Yun Dai, Sarah Tenorio, Jianghua Lu, Hisashi Harada, Paul Dent, Steven Grant

Blood (2007) 110 (6): 2092–2101.

https://doi.org/10.1182/blood-2007-04-083204

Published: 2007

Journal Articles

Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation

Yun Dai, Payal Khanna, Shuang Chen, Xin-Yan Pei, Paul Dent, Steven Grant

Blood (2007) 109 (10): 4415–4423.

https://doi.org/10.1182/blood-2006-09-047076

Published: 2007

Journal Articles

Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK

Yun Dai, Mohamed Rahmani, Xin-Yan Pei, Payal Khanna, Song Iy Han, Clint Mitchell, Paul Dent, Steven Grant

Blood (2005) 105 (4): 1706–1716.

https://doi.org/10.1182/blood-2004-07-2767

Published: 2005

Journal Articles

Highly Synergistic Interaction between Farnesyltransferase Inhibitors and the Chk1 Inhibitor UCN-01 to Induce Apoptosis in Human Leukemia Cells through Interruption of Both Akt and MEK/ERK Pathways and Activation of SEK1/JNK.

Yun Dai, Ph.D., Mohamed Rahmani, Ph.D., Xin-Yan Pei, M.D., Payal Khanna, Paul Dent, Ph.D., Steven Grant, M.D.

Blood (2004) 104 (11): 3403.

https://doi.org/10.1182/blood.V104.11.3403.3403

Published: 2004

NARROW

Dynamic Changes of Key Gene Mutations in the Disease Course of Patients with Chronic Myelomonocytic Leukemia

Dynamic Changes of Genetic Mutations in AML Patients from Diagnosis to Complete Remission and Relapse

Newly-Acquired and Clonally-Increased Mutations in TP53 and RAS Pathways Promote Progressive Disease and Leukemic Transformation in Patients with Myelodysplatic Neoplasms

Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy

Validation of the 5 th Edition of the World Health Organization Classification of Myelodysplastic Neoplasms on 852 Consecutive De Novo Patients from a Single Institute

Mutational Landscape, Clonal Evolution and Prognostic Effect of Non-Driver Mutations during Disease Progression of Primary Myelofibrosis

Unique Clinical Features and Mutation Profile in De Novo Myelodysplastic Syndromes with MF-1 and a Proposed Model for Distinguishing MDS with MF-2/3 from TN-PMF Based on Clinical and Genetic Covariates

Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis

Bim-Targeting Therapy Circumvents Adaptive Bortezomib-Resistance In Myeloma Through a Novel Cross-Link Between Autophagy and Apoptosis

Cytokinetically quiescent (G 0 /G 1 ) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2

Disruption of Src function potentiates Chk1-inhibitor–induced apoptosis in human multiple myeloma cells in vitro and in vivo

Bortezomib Interacts Synergistically with Belinostat to Induce Apoptosis In Human Acute Myeloid and Lymphoid Leukemia Cells

Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism.

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor–induced DNA damage in vitro and in vivo in human multiple myeloma cells

Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate

MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism

Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation

Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK

Highly Synergistic Interaction between Farnesyltransferase Inhibitors and the Chk1 Inhibitor UCN-01 to Induce Apoptosis in Human Leukemia Cells through Interruption of Both Akt and MEK/ERK Pathways and Activation of SEK1/JNK.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only